Provider Briefing: The Mercaptopurine Supply Situation in 2026

The Mercaptopurine (6-MP) shortage has been an ongoing challenge for prescribers since late 2023, and as of early 2026, it remains unresolved. For oncologists managing ALL maintenance protocols, gastroenterologists treating IBD, and other specialists who rely on this medication, the shortage creates real clinical dilemmas that require proactive management.

This briefing covers the current supply landscape, prescribing implications, available alternatives, and tools to help your patients maintain access to therapy.

Shortage Timeline

Here's how the Mercaptopurine shortage has evolved:

• Late 2023: Initial supply disruptions reported; ASHP adds Mercaptopurine tablets to its drug shortage list
• Early 2024: FDA acknowledges the shortage. Four of six supply solutions are in shortage or on allocation; one manufacturer discontinues production
• Mid-2024 through 2025: Intermittent availability continues. Pharmacies report allocation limits from wholesalers; patients experience significant difficulty filling prescriptions
• November 2025: Quinn Pharmaceuticals temporarily discontinues Mercaptopurine 50 mg tablets (25-count and 250-count bottles) with no estimated return date
• Early 2026: Shortage remains active. Remaining manufacturers (including Mylan and West-Ward/Hikma) continue production under allocation constraints

Prescribing Implications

The shortage affects clinical decision-making in several important ways:

Oncology (ALL Maintenance)

Mercaptopurine is a cornerstone of ALL maintenance chemotherapy. Interruptions in 6-MP therapy during maintenance can increase relapse risk. When supply is constrained:

• Confirm pharmacy stock before sending prescriptions — avoid prescriptions sitting unfilled
• Consider prescribing Purixan (oral suspension, 20 mg/mL) as a formulation alternative when tablets are unavailable
• If a true gap in therapy is unavoidable, document the clinical rationale and adjust protocol per institutional guidelines
• Consult with pharmacy about whether compounding from available Mercaptopurine powder is feasible (rare but possible in hospital settings)

Gastroenterology (IBD)

For patients on Mercaptopurine for Crohn's disease or ulcerative colitis maintenance:

• Azathioprine is the most straightforward substitution — it is a prodrug of Mercaptopurine and is generally more widely available
• Dose conversion: Azathioprine 2–2.5 mg/kg/day is roughly equivalent to Mercaptopurine 1–1.5 mg/kg/day (Azathioprine is approximately 88% converted to 6-MP)
• Monitor TPMT/NUDT15 status when switching — prior testing results should be in the chart, but confirm before initiating Azathioprine if not previously tested
• Methotrexate (15–25 mg/week, usually subcutaneous) is an alternative immunomodulator for patients who cannot access either thiopurine

Other Specialties (Rheumatology, Hepatology, Transplant)

For autoimmune hepatitis, rheumatoid arthritis, SLE, and transplant immunosuppression:

• Azathioprine is typically the first alternative, given its pharmacologic equivalence
• Mycophenolate mofetil (CellCept) may be considered for transplant and autoimmune indications
• Document the shortage as the reason for any therapeutic substitution for insurance and medical records

Current Availability Picture

The supply situation as of early 2026:

• Quinn Pharmaceuticals: Temporarily discontinued — no estimated return
• Other generic manufacturers: Producing but under allocation limits from major wholesalers (McKesson, Cardinal Health, AmerisourceBergen)
• Purixan (oral suspension): Available through specialty pharmacies; not subject to the same shortage as tablets, but significantly more expensive
• Regional variation: Availability varies significantly by geography and pharmacy type. Independent and specialty pharmacies may have better access than chain pharmacies

Cost and Access Considerations

The shortage has created financial strain alongside access challenges:

• Generic tablets (cash price): $400–$573 retail for 25 tablets; as low as $48–$56 with discount coupons
• Purixan: $2,000+ per month without insurance; may require prior authorization
• Insurance: Most plans cover generic Mercaptopurine at Tier 2 or 3. Prior authorization may be needed for Purixan or for off-label indications
• Help patients access patient assistance programs through NeedyMeds, RxAssist, or the PAN Foundation for cancer indications

Tools and Resources for Your Practice

Several resources can help you and your patients navigate the shortage:

Medfinder for Providers

Medfinder offers real-time pharmacy availability data that can help your office staff identify pharmacies with Mercaptopurine in stock before sending prescriptions. This reduces the cycle of rejected fills and patient callbacks.

ASHP Drug Shortage Database

The ASHP Drug Shortages Resource Center provides regularly updated shortage information, including manufacturer status, estimated resupply dates, and therapeutic alternatives.

FDA Drug Shortage Database

The FDA's shortage database tracks the same information from a regulatory perspective and may have additional detail on manufacturing timelines.

Proactive Prescribing Tips

• Verify pharmacy stock before writing prescriptions for shortage medications
• Include the indication on the prescription — this helps pharmacies prioritize allocation and facilitates insurance coverage
• Consider writing for 90-day supplies when stock is available, to reduce the frequency of refill-related gaps
• Establish a relationship with a specialty pharmacy for your oncology/GI patients who need reliable access

Looking Ahead

There is no confirmed resolution date for the Mercaptopurine shortage. FDA monitoring continues, and any new manufacturer entries or production ramp-ups will be reflected in the ASHP database. In the meantime, proactive prescribing, clear patient communication, and familiarity with alternatives remain the best strategies.

For provider-specific tools and resources, visit medfinder.com/providers.

Final Thoughts

Drug shortages are one of the most frustrating aspects of modern healthcare. For a medication as critical as Mercaptopurine — used in cancer maintenance and chronic disease management — the impact on patients is real and significant. By staying informed and leveraging the tools available, you can help your patients maintain continuity of care even during a prolonged shortage.

Related resources for your patients:

• Mercaptopurine shortage update for patients
• How to find Mercaptopurine in stock
• Alternatives to Mercaptopurine